Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Arev Nutrition Sciences set to acquire cannabis strain company BC Bud Depot in C$5.25mln deal

BCBD has one of the world's largest seed banks and has won over 40 awards over the past 14 years.
Arev Nutrition Sciences set to acquire cannabis strain company  BC Bud Depot in C$5.25mln deal
BCBD has one of the globe's largest seed banks

Arev Nutrition Sciences Inc (CSE:AREV) is set to buy cannabis strain-focused  BC Bud Depot (BCBD) in a C$5.25mln deal, which provides the company with immediate revenue in legal jurisdictions, it said.

BCBD has one of the world's largest seed banks and has won over 40 awards over the past 14 years. Its breeding methods for new cannabis strains are available for licence to licenced production companies.

AREV also noted that in 2004, it was the first Canadian company in history to win a top strain at international competition with 'BC God Bud'.It has held the inside cover of High Times Magazine for the last ten years and remains among the most recognised names in cannabis genetics and breeding.

"This acquisition brings AREV into immediate revenue in legal jurisdictions. It also completes a very important part of the company's strategy to differentiate from cultivators while bringing them a secure source of revenue," Mike Withrow, director at AREV, told investors.

"This ensures that AREV will have consistent raw materials for ingredients that are extracted from the specific genetics grown for targeted areas of health and recreational experiences.

"These extracts will be used in the company's formula's for finished products and marketed in legal jurisdictions throughout the world."

The consideration is for 9.5mln AREV shares at a deemed price of 50 cents per share and C$500,000, of which $50,000 is payable in cash and C$450,000 is payable by way of a convertible debenture issued by the company, accruing interest at 8% per year, for a total value of C$5.25mln.

BC BUD Depot added: "This partnership allows us to accelerate breeding programs designed to improve existing strains and to release new cannabis strains likely to perform well in regulated markets both within Canada and, through licensed exports of genetic material, in legal jurisdictions worldwide."

German unit

Also in today's news release, the firm said it had acquired DEUTSCHE MEDIZINAL CANNABIS UG (DMC), which will become the group's wholly owned German subsidiary.

This is a strategic purchase as the procedure for granting production and distribution licenses for medical cannabis in Germany has been halted by a court decision and no licenses have been granted to any company in Germany.

DMC is one out of only 26 companies (of 118 that participated) which had been considered eligible by the relevant ministry, at all.

The acquisition cost €18,000 paid to four vendors, AREV said.

Shares were unchanged at C$0.56.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full AREV profile View Profile

Arev Brands International Ltd. Timeline

Related Articles

pizza being forked
Tue
First-half results revealed significant progress was made both financially and operationally

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use